OncoZenge
5.70 SEK
-0.35 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.35 %
-7.47 %
-15.68 %
-15.68 %
+1.42 %
+5.56 %
-22.97 %
-49.11 %
-53.42 %
OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Read moreMarket cap
80.07M SEK
Turnover
16.18K SEK
Revenue
2.66M
EBIT %
-592.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20/5
2026
Interim report Q1'26
27/5
2026
General meeting '26
27/8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial
Intervju med OncoZenge's VD under SCF:s 17:e Kapitalmarknadsdag Life Science
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
